| COMPARISON
OF RELATIVE RENAL FUNCTION MEASURED WITH EITHER 99mTc-DTPA
OR 99mTc-EC DYNAMIC SCINTIGRAPHIES WITH THAT MEASURED WITH
99mTc-DMSA STATIC SCINTIGRAPHY
(
Download pdf )
F. C. DOMINGUES,
G. Y. FUJIKAWA, H. DECKER, G. ALONSO, J. C. PEREIRA, P. S. DUARTE
Section of
Nuclear Medicine, Fleury Diagnostic Center and Department of Epidemiology,
Health Public School, University of Sao Paulo, USP, Sao Paulo, SP, Brazil
ABSTRACT
Objective:
The aim of this study was to compare the renal function measured with
either 99mTc-DTPA or 99mTc-EC dynamic scintigraphies
with that measured using 99mTc-DMSA static scintigraphy.
Methods: the values of relative renal function
measured in 111 renal dynamic scintigraphies performed either with 99mTc-DTPA
(55 studies) or with 99mTc-EC (56 studies) were compared with
the relative function measured using 99mTc-DMSA static scintigraphy
performed within a 1-month period. The comparisons were performed using
Wilcoxon signed rank test. The number of 99mTc-DTPA and 99mTc-EC
studies that presented relative renal function different by more than
5% from that measured with 99mTc-DMSA, using chi square test
were also compared.
Results: the relative renal function measured
with 99mTc-EC is not statistically different from that measured
with 99mTc-DMSA (p = 0.97). The relative renal function measured
with 99mTc-DTPA was statistically different from that measured
using 99mTc-DMSA, but with a borderline statistical significance
(p = 0.05). The number of studies with relative renal function different
by more than 5% from that measured with 99mTc-DMSA is higher
for the 99mTc-DTPA scintigraphy (p = 0.04) than for 99mTc-EC.
Conclusion: the relative renal function
measured with 99mTc-EC dynamic scintigraphy is comparable with
that measured with 99mTc-DMSA static scintigraphy, while the
relative renal function measured with 99mTc-DTPA dynamic scintigraphy
presents a significant statistical difference from that measured with
99mTc-DMSA static scintigraphy.
Key
words: kidney function tests; scintigraphy; DTPA, DMSA
Int Braz J Urol. 2006; 32: 405-9
INTRODUCTION
Renal
scintigraphies have been used for a long time to measure the relative
renal function. These methods can be performed with different radiopharmaceuticals
as technetium-99m dimercaptosuccinic acid (99mTc-DMSA), technetium-99m
diethylenetriamine pentaacetic acid (99mTc-DTPA), technetium-99m
mercaptoacetyltriglycine (99mTc-MAG3), iodine 131 orthoiodohippurate
(OIH) and more recently technetium-99m ethylenedicysteine (99mTc-EC)
(1). Although all these methods are accurate to measure this parameter,
some differences can be observed among them (2). These differences are
caused by distinct biological properties of radiopharmaceuticals such
as mechanisms of renal excretion, renal cells retention of radioactive
material, level of plasma-protein bound and level of plasmatic clearance.
However, 99mTc-DMSA as a static renal agent is considered the
most reliable method to measure relative renal function (3-5) and the
most appropriate tracer for renal cortical imaging (6).
Recently, a new radiopharmaceutical (99mTc-EC)
has been developed to perform renal dynamic scintigraphy and to measure
renal relative function. It has similar renal excretion characteristics
to 99mTc-MAG3 and OIH (7). This radiopharmaceutical has been
available for clinical use in Brazil since 2004 and has been used as a
substitute for 99mTc-DTPA to perform the studies. In our subjective
experience, 99mTc-EC appears to be superior to 99mTc-DTPA
to perform the exams. However, there is few data about the comparison
of these two methods on medical literature. Therefore, the aim of this
study was to analyze the dynamic renal scintigraphies performed either
with 99mTc-EC or with 99mTc-DTPA to assess if the
relative renal functions measured by both methods are similar when compared
to that measured using 99mTc-DMSA.
MATERIALS
AND METHODS
We
analyzed 111 patients, 52 males, age ranging from 0.17 to 79.00 years
(Table-1). A hundred and eleven renal dynamic scintigraphies performed
either with 99mTc-DTPA (55 studies) or with 99mTc-EC
(56 studies) were compared to the relative function measured using 99mTc-DMSA
static scintigraphy performed within a 1-month period (Table-1).
99mTc-DTPA and 99mTc-EC
dynamic images were acquired with the patients in a supine position and
with gamma camera’s detector placed in a posterior view. The camera
was equipped with an all-purpose, low energy, parallel-hole collimator.
Adult patients were injected with 370 to 555 MBq of 99mTc-DTPA
or 99mTc-EC, and dynamic images were recorded every second
for 1 minute and every 15 seconds for 30 minutes. Relative renal function
was measured in a composite image (1 to 3 minutes after the injection).
Renal and background regions of interest (ROIs) were drawn manually by
a skilled nuclear medicine technologist (Figure-1).
99mTc-DMSA static images were
also acquired with the patients in a supine position and with gamma camera’s
detector placed in a posterior view. The camera was also equipped with
an all-purpose, low energy, parallel-hole collimator. Adult patients were
injected with 222 MBq of the radiopharmaceutical and static images were
acquired 6 hours after in the posterior, left posterior oblique and right
posterior oblique projections. Relative renal function was measured in
the posterior image. Renal regions of interest (ROIs) were drawn manually
by a skilled nuclear medicine technologist and the background regions
of interest (ROIs) were drawn automatically by the processing program
(Figure-2).
For pediatric patients injected activities
were adjusted using the “Pediatric Dose Chart for Radiopharmaceuticals”
presented on “The Mayo Clinic Manual of Nuclear Medicine”
(8).
Procedures used to acquire and process the
images were based on the experience of our nuclear medicine service, on
the published experience of others nuclear medicine services (9) and on
the Procedure Guidelines of the European Association of Nuclear Medicine
and of the Society of Nuclear Medicine (www.eanm.org
and www.interactive.snm.org).
Comparison of relative renal function measurement
using either 99mTc-DTPA or 99mTc-EC dynamic scintigraphies
with the one measured using 99mTc-DMSA static scintigraphy
was performed using non-parametric test for related samples (Wilcoxon
signed rank test). The number of 99mTc-DTPA and 99mTc-EC
studies that presented relative renal function different by more than
5% from the relative function measured with 99mTc-DMSA, using
chi square statistical test was also compared. To rule out confounding,
the two groups of patients who underwent dynamic scintigraphy (99mTc-DTPA
and 99mTc-EC) were also compared to assess if there were differences
in others parameters. Parameters analyzed were sex, age, and relative
renal function (between them, as well as between the correspondent 99mTc-DMSA
studies). Comparisons between groups were performed using a non-parametric
test for independent samples (Mann-Whitney) when variables were continuous
and chi square test when variables were categorical (sex).
RESULTS
Relative
renal function measured with 99mTc-EC was not statistically
different from that measured with 99mTc-DMSA (p = 0.97). Relative
renal function measured with 99mTc-DTPA was distinct from that
measured with 99mTc-DMSA, but with a marginal statistical significance
(p = 0.05). The number of studies with relative renal function different
by more than 5% from the one measured with 99mTc-DMSA is higher
for the 99mTc-DTPA scintigraphy (10 in 55) than for 99mTc-EC
(3 in 56) (p = 0.04). There was no significant statistical difference
in the control parameters between the two groups (99mTc-DTPA
and 99mTc-EC): sex (p = 0.22), age (p = 0.58), left and right
kidney functions in dynamic scintigraphies (p = 0.22), and left and right
kidney functions in static scintigraphies (p = 0.15).
DISCUSSION
As
already mentioned on the introduction, there are few papers comparing
99mTc-DTPA with 99mTc-EC. In a MEDLINE search (October
06, 2005) using key words (DTPA AND EC AND Scintigraphy AND Renal) only
one paper comparing the two methods was retrieved (10). This paper compares
the diagnostic accuracy of 99mTc-EC with 99mTc-DTPA
in the assessment of renal artery stenosis. It concludes that although
there is no significant difference between 99mTc-EC and 99mTc-DTPA
captopril scintigraphy for detecting renal artery stenosis, the better
imaging characteristics and more confident interpretation provided by
99mTc-EC make it a preferential radiopharmaceutical to perform
the scintigraphy. There are also studies (11,12) comparing relative renal
function measured with 99mTc-EC and 99mTc-DMSA showing
a high correlation between these two methods.
In our group of patients, relative renal
function measured with 99mTc-EC appears to be more accurate
than the one measured with 99mTc-DTPA, if the 99mTc-DMSA
static scintigraphy is considered the “gold standard” method.
One reason for this difference may be the different mechanisms of renal
excretion for these radiopharmaceuticals (99mTc-DTPA is excreted
by glomerular filtration whereas 99mTc-EC and 99mTc-DMSA
are excreted primarily by proximal convoluted tubules). Although these
two mechanisms of excretion are highly correlated, they are not identical
and some patients could have a more pronounced impairment in one of them
(13,14). Another possible reason for this difference is the higher level
of background activity (extra-renal activity) presented in dynamic renal
scintigraphy with 99mTc-DTPA due to its low extraction efficiency
(20%) when compared to the tubular secreted radiopharmaceuticals (15).
CONCLUSION
Relative
renal function measured with 99mTc-EC dynamic scintigraphy
is comparable to that measured with 99mTc-DMSA static scintigraphy,
while relative renal function measured with 99mTc-DTPA dynamic
scintigraphy presents a statistical significant difference from that measured
with 99mTc-DMSA static scintigraphy.
CONFLICT
OF INTEREST
None declared.
REFERENCES
- Moran JK: Technetium-99m-EC and other potential new agents in renal
nuclear medicine. Semin Nucl Med. 1999; 29: 91-101.
- Taylor A Jr, Lallone R: Differential renal function in unilateral
renal injury: possible effects of radiopharmaceutical choice. J Nucl
Med. 1985; 26: 77-80.
- Ardela Diaz E, Miguel Martinez B, Gutierrez Duenas JM, Diez Pascual
R, Garcia Arcal D, Dominguez Vallejo FJ: Comparative study of differential
renal function by DMSA and MAG-3 in congenital unilateral uropathies.
Cir Pediatr. 2002; 15: 118-21.
- Kawashima A, Sandler CM, Goldman SM: Current roles and controversies
in the imaging evaluation of acute renal infection.World J Urol. 1998;
16: 9-17.
- Piepsz A: Cortical scintigraphy and urinary tract infection in children.
Nephrol Dial Transplant. 2002; 17: 560-2.
- Piepsz A, Blaufox MD, Gordon I, Granerus G, Majd M, O’Reilly
P, et al.: Consensus on renal cortical scintigraphy in children with
urinary tract infection. Scientific Committee of Radionuclides in Nephrourology.
Semin Nucl Med. 1999; 29: 160-74.
- Ozker K, Onsel C, Kabasakal L, Sayman HB, Uslu I, Bozluolcay S, et
al.: Technetium-99m-N,N-ethylenedicysteine—a comparative study
of renal scintigraphy with technetium-99m-MAG3 and iodine-131-OIH in
patients with obstructive renal disease. J Nucl Med. 1994; 35: 840-5.
- O’Connor MK, Hung JC: Pediatric Dose Chart for Radiopharmaceuticals
(Children Less Than 18 Years of Age). In: O’Connor MK, (ed.),
The Mayo Clinic Manual of Nuclear Medicine. New York, Churchill Livingstone.
1996; pp. 565-9.
- O’Connor MK: The Mayo Clinic Manual of Nuclear Medicine. New
York, Churchill Livingstone. 1996.
- Ugur O, Serdengecti M, Karacalioglu O, Peksoy I, Cekirge S, Aslan
N, et al.: Comparison of Tc-99m EC and Tc-99m DTPA captopril scintigraphy
to diagnose renal artery stenosis. Clin Nucl Med. 1999; 24: 553-60.
- Atasever T, Ozkaya O, Abamor E, Soylemezoglu O, Buyan N, Unlu M:
99mTc ethylene dicysteine scintigraphy for diagnosing cortical
defects in acute pyelonephritis: a comparative study with 99mTc
dimercaptosuccinic acid. Nucl Med Commun. 2004; 25: 967-70.
- Kibar M, Yapar Z, Noyan A, Anarat A: Technetium-99m-N,N-ethylenedicysteine
and Tc-99m DMSA scintigraphy in the evaluation of renal parenchymal
abnormalities in children. Ann Nucl Med. 2003; 17: 219-25.
- De Geeter F, Saelens E, Van Steelandt H, Degomme P: Differential
renal uptake of technetium-99m-DMSA and technetium-99m-DTPA. J Nucl
Med. 1993; 34: 1217-8.
- Quinn RJ, Elder GJ: Poor technetium-99m-DMSA renal uptake with near
normal technetium-99m-DTPA uptake caused by tubulointerstitial renal
disease. J Nucl Med. 1991; 32: 2273-4.
- Taylor A: Radionuclide renography: a personal approach. Semin Nucl
Med. 1999; 29: 102-27.
____________________
Accepted after revision:
April 26, 2006
_______________________
Correspondence address:
Dr. Paulo S. Duarte
Seção de Medicina Nuclear
Rua Cincinato Braga, 232
01333-910, São Paulo, SP, Brazil
Fax: + 55 11 5014-6788
E-mail: paulo.duarte@fleury.com.br |